Zahra Taheri1, Hamid Asadzadeh Aghdaei2, Shiva Irani3, Mohammad Hossein Modarressi4, Zahra Noormohammadi1. 1. Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran. 2. Basic and Molecular Epidemiology of Gastroenterology Disorders Research Center,Research Institute for Gastroenterology and Liver Diseases,Shahid Beheshti University of Medical Sciences,Tehran,Iran. 3. Department of Biology, Science and Research Branch, Islamic Azad University,Tehran,Iran. 4. Department of Medical Genetics, School of Medicine,Tehran University of Medical Sciences,Tehran,Iran.
Abstract
BACKGROUND: Abnormal DNA methylation leading to altered transcription of certain genes occurs frequently in colorectal cancer (CRC). As with protein-coding genes, microRNAs (miRNAs) may be targeted for methylation in CRC; however, the methylation state of miRNA genes in CRC, especially in primary lesions, has not yet been completely elucidated. To understand the impact of DNA methylation on the miR-200c/141 cluster promoter, we investigated the methylation and expression of miR-141 in precancerous lesions and colorectal cancer. METHODS: In this cross-sectional study, 208 colorectal tissue samples, including 34 tumor tissue samples, 60 precancerous lesions with matched normal adjacent tissues, and 20 normal tissue samples, were collected. Promoter methylation of the miR-200c/141 cluster was studied using methylation-specific PCR. MiR-141 expression was examined using quantitative real-time PCR. RESULTS: Our findings showed that the miR-200c/141 cluster promoter region was most frequently hypermethylated in colorectal tumors and adenomatous polyps, but unmethylated in hyperplastic polyp tissues (P < 0.001). DNA methylation of the miR-200c/141 cluster and the tumor stage were significantly correlated (P = 0.002); however, miR-141 expression difference between the tumor and polyp samples was not significant (p = 0.6). CONCLUSION: The DNA methylation status of the miR-200c/141 cluster could serve as a progression marker from benign polyps to colorectal cancer.
BACKGROUND: Abnormal DNA methylation leading to altered transcription of certain genes occurs frequently in colorectal cancer (CRC). As with protein-coding genes, microRNAs (miRNAs) may be targeted for methylation in CRC; however, the methylation state of miRNA genes in CRC, especially in primary lesions, has not yet been completely elucidated. To understand the impact of DNA methylation on the miR-200c/141 cluster promoter, we investigated the methylation and expression of miR-141 in precancerous lesions and colorectal cancer. METHODS: In this cross-sectional study, 208 colorectal tissue samples, including 34 tumor tissue samples, 60 precancerous lesions with matched normal adjacent tissues, and 20 normal tissue samples, were collected. Promoter methylation of the miR-200c/141 cluster was studied using methylation-specific PCR. MiR-141 expression was examined using quantitative real-time PCR. RESULTS: Our findings showed that the miR-200c/141 cluster promoter region was most frequently hypermethylated in colorectal tumors and adenomatous polyps, but unmethylated in hyperplastic polyp tissues (P < 0.001). DNA methylation of the miR-200c/141 cluster and the tumor stage were significantly correlated (P = 0.002); however, miR-141 expression difference between the tumor and polyp samples was not significant (p = 0.6). CONCLUSION: The DNA methylation status of the miR-200c/141 cluster could serve as a progression marker from benign polyps to colorectal cancer.
Entities:
Keywords:
Colonic Polyps; Colorectal Cancer; DNA methylation; MiR-141
Authors: Erik D Wiklund; Jesper B Bramsen; Toby Hulf; Lars Dyrskjøt; Ramshanker Ramanathan; Thomas B Hansen; Sune B Villadsen; Shan Gao; Marie S Ostenfeld; Michael Borre; Marcus E Peter; Torben F Ørntoft; Jørgen Kjems; Susan J Clark Journal: Int J Cancer Date: 2011-03-15 Impact factor: 7.396
Authors: Gang Zhao; Bo Wang; Yang Liu; Jun-Gang Zhang; Shi-Chang Deng; Qi Qin; Kui Tian; Xiang Li; Shuai Zhu; Yi Niu; Qiong Gong; Chun-You Wang Journal: Mol Cancer Ther Date: 2013-09-06 Impact factor: 6.261
Authors: Mari Øines; Lise M Helsingen; Michael Bretthauer; Louise Emilsson Journal: Best Pract Res Clin Gastroenterol Date: 2017-06-28 Impact factor: 3.043
Authors: Ahmedin Jemal; Freddie Bray; Melissa M Center; Jacques Ferlay; Elizabeth Ward; David Forman Journal: CA Cancer J Clin Date: 2011-02-04 Impact factor: 508.702
Authors: Humberto J Ferreira; Veronica Davalos; Manuel Castro de Moura; Marta Soler; Montserrat Perez-Salvia; Alberto Bueno-Costa; Fernando Setien; Sebastian Moran; Alberto Villanueva; Manel Esteller Journal: Oncotarget Date: 2018-06-26